NCT05100056 (BV-MAZOVIA) is a clinical trial of No Intervention in Hodgkin Lymphoma, sponsored by Takeda.

Who is sponsoring NCT05100056?

NCT05100056 is sponsored by Takeda.

What drugs are being tested in NCT05100056?

Interventions in NCT05100056: No Intervention.

What condition does NCT05100056 study?

NCT05100056 studies Hodgkin Lymphoma.

Is NCT05100056 still recruiting?

NCT05100056 is currently recruiting now. Last updated 9 September 2025.

Last reviewed 2025-09-09 · How we verify

NCT05100056: BV-MAZOVIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Brentuximab Vedotin in Adults With Hodgkin's Lymphoma

Recruiting now Last updated 9 September 2025

What this trial tests

trial testing No Intervention in Hodgkin Lymphoma in 70 participants. Currently enrolling.

Timeline

8 March 2022

Primary endpoint
1 June 2026

1 June 2026

Quick facts

Lead sponsor	Takeda
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	70
Start date	8 March 2022
Primary completion	1 June 2026
Estimated completion	1 June 2026
Sites	13 locations across Poland

Drugs / interventions tested

No Intervention

Conditions studied

Hodgkin Lymphoma — all drugs for Hodgkin Lymphoma →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The main aim is to check how effective BV is for treating adults with HL. Study medication will be prescribed according to the clinic's standard practice. Participants will visit the study clinic 5 times, once every 12 weeks. When study treatment has completed, a follow-up visit will be scheduled every 3 months during the first year and every 4-6 months during the next year.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas.
Li Z, Guo W, Bai O. · · 2023 · cited 11× · PMID 38188299 · DOI 10.3389/fonc.2023.1301437
Efficiency and Safety of Brentuximab Vedotine as a Salvage Treatment Before Autologous Stem Cell Transplantation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: Retrospective Study.
Filonenko K, Stepanishyna Y, Shokun N, Martynchyk A, et al · · 2025 · PMID 41141992 · DOI 10.1155/ah/3573471

Verify or expand the search:

Other trials of No Intervention

Trials testing the same drug.

NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting

Other recruiting trials for Hodgkin Lymphoma

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT06176690 — Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas · Phase 1 · recruiting
NCT07002216 — BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma · Phase 2 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05100056 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 9 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05100056.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing